ADC Wins Accelerated Approval for TNBC

]]>(MedPage Today) -- WASHINGTON--The FDA granted accelerated approval to the antibody-drug conjugate (ADC) sacituzumab govitecan (Trodelvy) for previously treated metastatic triple-negative breast cancer (TNBC).Sacituzumab govitecan consists...